That pipeline AbbVie acquired in the $63B Allergan buyout? It’s not doing so well
Another Allergan project picked up by AbbVie in their $63 billion buyout has turned sour.
UroGen $URGN reported Thursday morning that a Phase II study using their RTGel product to apply Botox to stop overactive bladder and urinary incontinence has failed. AbbVie had been in charge of the study after completing the Allergan deal a few months ago.
UroGen execs pinned the blame on Botox, saying that the data suggest that the wrinkle therapy hadn’t effectively permeated the urothelium, or bladder wall, preventing efficacy. And they went on to tout their product, already on the market for urothelial cancer, as a winner.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.